According to Gram Research analysis, vitamin D deficiency affects about 80% of cancer patients, but a distinct condition called functional vitamin D resistance—where the body can’t use vitamin D properly—occurs in only 3.9% of patients. This resistance is linked to diabetes and high cholesterol rather than cancer stage, suggesting doctors should check PTH hormone levels alongside vitamin D to determine if patients can actually benefit from supplementation.
A new study of 220 cancer patients reveals that vitamin D deficiency is extremely common, but some patients have a special problem called “functional vitamin D resistance” where their bodies can’t use vitamin D properly, even when levels seem normal. Researchers found that this resistance happens in about 4% of cancer patients and is linked to diabetes and cholesterol problems. The study suggests doctors should check a hormone called PTH along with vitamin D levels to better understand how well patients can actually use vitamin D. This could help doctors give better treatment recommendations for cancer patients.
Key Statistics
A 2026 observational study of 220 cancer patients found that 80% had vitamin D deficiency or insufficiency, with an average vitamin D level of 22.2 ng/mL, indicating widespread vitamin D problems in cancer populations.
Among 206 evaluable cancer patients in a 2026 study, functional vitamin D resistance was identified in 3.9% and was significantly associated with type 2 diabetes and dyslipidemia, but not with cancer stage or metastatic status.
A 2026 analysis of 220 cancer patients found that serum vitamin D levels were inversely correlated with PTH levels (p = 0.005), suggesting that measuring both markers provides better insight into vitamin D responsiveness than vitamin D alone.
The Quick Take
- What they studied: Whether cancer patients with low vitamin D levels respond normally to vitamin D, or if some have a condition where their bodies can’t use vitamin D properly even when they take supplements.
- Who participated: 220 cancer patients (average age 57.6 years) being treated at an integrative cancer center in India. The group included people with different types of cancer, at different stages of disease.
- Key finding: About 80% of cancer patients had low vitamin D levels, but only 4% had a special condition called functional vitamin D resistance where their bodies couldn’t use vitamin D properly. This resistance was linked to diabetes and high cholesterol, not to cancer stage.
- What it means for you: If you have cancer and low vitamin D, taking supplements may help—but your doctor should also check your PTH hormone levels to see if your body can actually use the vitamin D. This is especially important if you also have diabetes or cholesterol problems.
The Research Details
Researchers looked back at medical records from 220 cancer patients to see how much vitamin D they had in their blood and how their bodies responded to it. They measured two things: vitamin D levels (called 25-hydroxyvitamin D) and a hormone called PTH that shows whether the body is responding to vitamin D properly. They compared these measurements across different groups—patients with different cancer types, different disease stages, and different health conditions like diabetes and high cholesterol.
This type of study is called a retrospective observational analysis, which means researchers examined existing medical data rather than conducting a new experiment. While this approach is faster and less expensive than a new study, it can only show patterns and connections, not prove that one thing causes another.
The researchers were looking for a specific pattern: patients who had normal or high PTH levels even though their vitamin D was low. This pattern would suggest their bodies weren’t responding properly to vitamin D—a condition they called functional vitamin D resistance.
Most doctors only check vitamin D levels, but vitamin D is just one part of a system. When vitamin D is low, the body should naturally produce more PTH to compensate. If PTH stays high even when vitamin D is supplemented, it suggests the body’s vitamin D system isn’t working right. This approach helps doctors understand not just how much vitamin D patients have, but whether their bodies can actually use it.
This study has several strengths: it included 220 patients with detailed medical records, it measured both vitamin D and PTH (not just one), and it looked at how different health conditions affected vitamin D response. However, because it’s a retrospective study looking at past records, it can’t prove cause-and-effect relationships. The study was done at one center in India, so results may not apply equally to all populations. The researchers did not randomly assign patients to treatment groups, so some differences might be due to other factors they didn’t measure.
What the Results Show
The study found that vitamin D deficiency and insufficiency are extremely common in cancer patients. The average vitamin D level was 22.2 ng/mL, which is quite low (normal is above 30 ng/mL). About 80% of the 220 patients had vitamin D levels that were either deficient or insufficient.
More importantly, the researchers identified a distinct group of patients with functional vitamin D resistance—a condition where the body doesn’t respond properly to vitamin D. This was found in only 8 out of 206 patients (3.9%), making it relatively rare but clinically important. These patients had a specific pattern: their PTH hormone remained elevated even though they had vitamin D supplementation, suggesting their bodies couldn’t properly use the vitamin D.
The study found that advanced cancer stage was independently linked to vitamin D deficiency, meaning patients with more advanced disease were more likely to have low vitamin D. Interestingly, patients with dyslipidemia (high cholesterol) were actually less likely to have vitamin D deficiency, which was unexpected and suggests a complex relationship between metabolic health and vitamin D.
Functional vitamin D resistance was significantly associated with type 2 diabetes and dyslipidemia, but not with cancer stage or whether cancer had spread. This suggests that metabolic conditions, not the cancer itself, may be the key factor in whether a patient’s body can use vitamin D properly.
The study found a significant inverse correlation between vitamin D levels and PTH levels (p = 0.005), meaning as vitamin D went down, PTH went up—which is the normal expected pattern. However, in the small group with functional vitamin D resistance, this normal pattern was disrupted. The researchers noted that measuring PTH alongside vitamin D provides additional information about how well the vitamin D system is actually working in cancer patients.
Previous research has shown that vitamin D deficiency is common in cancer patients and that low vitamin D is associated with worse outcomes. However, most studies only measured vitamin D levels without assessing whether patients’ bodies could actually use the vitamin D. This study adds an important new concept: functional vitamin D resistance, which explains why some cancer patients don’t improve even when given vitamin D supplements. The finding that metabolic conditions like diabetes and high cholesterol are linked to vitamin D resistance aligns with emerging research showing that metabolic health affects how the body processes vitamin D.
This study has several important limitations. First, it’s a retrospective analysis, meaning researchers looked at past medical records rather than following patients forward in time. This makes it impossible to prove that metabolic conditions cause vitamin D resistance—only that they’re associated. Second, the study was conducted at a single center in India, so results may not apply equally to cancer patients in other countries or populations. Third, the study didn’t track whether patients actually took vitamin D supplements or how much they took, so we don’t know if functional vitamin D resistance was truly about the body’s inability to respond or about other factors. Finally, only 206 of the 220 patients had complete data for the functional vitamin D resistance analysis, which is a relatively small number for drawing firm conclusions about this rare condition.
The Bottom Line
If you have cancer and low vitamin D levels, ask your doctor about vitamin D supplementation—the evidence supports this. However, ask your doctor to also check your PTH levels, especially if you have diabetes or high cholesterol. This combined approach gives a more complete picture of whether your body can actually use vitamin D. If you have functional vitamin D resistance (which is rare), your doctor may need to adjust your treatment approach. Confidence level: Moderate for vitamin D supplementation in general; Lower for the specific PTH testing approach, as this is a newer concept.
Cancer patients with low vitamin D levels should pay attention to this research, particularly those who also have type 2 diabetes or high cholesterol. Oncologists and integrative medicine doctors should consider checking PTH levels alongside vitamin D in cancer patients. People without cancer may also benefit from this approach if they have metabolic conditions and low vitamin D. This research is less relevant for people with normal vitamin D levels.
If you start vitamin D supplementation, it typically takes 8-12 weeks to see changes in blood vitamin D levels. However, if you have functional vitamin D resistance, supplementation alone may not work, and your doctor may need to address underlying metabolic conditions like diabetes or high cholesterol first. Improvements in metabolic health may take several months to show effects on vitamin D responsiveness.
Frequently Asked Questions
Why don’t some cancer patients respond to vitamin D supplements even when their levels are low?
Some cancer patients have functional vitamin D resistance, a condition where their bodies can’t properly use vitamin D even when supplemented. This occurs in about 4% of cancer patients and is linked to diabetes and high cholesterol rather than the cancer itself. Testing PTH levels alongside vitamin D can identify this problem.
How common is vitamin D deficiency in cancer patients?
A 2026 study of 220 cancer patients found that approximately 80% had vitamin D deficiency or insufficiency, with an average level of 22.2 ng/mL. This makes vitamin D deficiency one of the most common nutritional problems in cancer populations.
Should cancer patients with diabetes be more concerned about vitamin D?
Yes. A 2026 study found that functional vitamin D resistance was significantly associated with type 2 diabetes. Cancer patients with diabetes should ask their doctors to check both vitamin D and PTH levels, as they may have difficulty using vitamin D supplements effectively.
What does PTH have to do with vitamin D levels in cancer patients?
PTH is a hormone that regulates vitamin D function. When vitamin D is low, PTH should rise to compensate. In patients with functional vitamin D resistance, PTH stays high even after vitamin D supplementation, indicating the body isn’t responding properly. Measuring both provides a complete picture of vitamin D responsiveness.
Does cancer stage affect how well patients can use vitamin D?
Advanced cancer stage is associated with vitamin D deficiency, but functional vitamin D resistance—the inability to use vitamin D—is not linked to cancer stage. Instead, it’s associated with metabolic conditions like diabetes and high cholesterol, suggesting different underlying causes.
Want to Apply This Research?
- Track your vitamin D supplementation dose and frequency, along with any PTH or vitamin D blood test results. Record this monthly and note any changes in energy levels, bone health, or immune function. Include dates of blood tests and the actual lab values.
- If your doctor recommends vitamin D supplementation, set a daily reminder in the app to take your supplement at the same time each day. Log when you take it and any side effects. If you have diabetes or high cholesterol, also track your management of these conditions (medication adherence, diet choices) since these may affect how your body uses vitamin D.
- Schedule vitamin D and PTH blood tests every 3-6 months and log the results in the app. Create a trend chart to see if your levels are improving. If you have metabolic conditions, track those separately and look for correlations between improvements in cholesterol or blood sugar and changes in vitamin D responsiveness.
This research describes patterns observed in one cancer center and should not replace personalized medical advice from your oncologist or healthcare provider. Vitamin D supplementation decisions should be made with your doctor, especially if you have diabetes, high cholesterol, or other metabolic conditions. This study does not establish cause-and-effect relationships and represents preliminary findings that require further research. Always consult with your healthcare team before starting any new supplement regimen, as vitamin D can interact with certain medications and conditions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.